Učitavanje...
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
BACKGROUND: Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20–40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and...
Spremljeno u:
| Izdano u: | Front Oncol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5625582/ https://ncbi.nlm.nih.gov/pubmed/29034210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00233 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|